Alentis is the only company developing potential treatments for solid cancers and fibrosis targeting Claudin-1 (CLDN1). The molecule is significantly involved in the tight junction between cells. Now the company closed a three digit million Seriec C round.
BioNTech has entered the ADC field with an exclusive license and collaboration agreement with China’s DualityBio Ltd for two antibody-drug conjugate (ADC) assets.
The charity Cancer Research UK and UCB SA collaborate on the development of two potential cures for cancer.
SOTIO Biotech a.s. has exercised its first of five exclusive, target-specific options for antibody-drug conjugate (ADC) SOT106 under its agreement with LegoChem Biosciences Inc.
In a deal worth around USD435m Swiss ADC therapeutics grants Swedish Orphan Biovitrum (SOBI) the rights to market freshly approved Zynlonta outside the US.